Staff

Position Statements on the Use of Biosimilars in the Ministry of Health, Malaysia Healthcare Facilities

Date: 15 October 2023 - 5:21am

The increasing use of biological medicines including biosimilars in the Ministry of Health (MOH), Malaysia facilities warrants a suitable guidance document to ensure safe

English

#MedSafetyWeek 2022

During the annual #MedSafetyWeek global campaign, National Pharmaceutical Regulatory Agency (NPRA) collaborates with the Uppsala Monitoring Centre (UMC, the World Health Organisation (WHO) Collaborating Centre for International Drug Monitoring), medicines regulatory authorities, and national pharmacovigilance centres around the world to raise awareness of medication safety and encourage reporting of suspected adverse drug reactions/adverse events following immunisation (ADR/AEFI).

Location/place: 
Online
Date: 
Monday, 7 November 2022 to Sunday, 13 November 2022

PENGUMUMAN: GARIS PANDUAN KELULUSAN PENGIKLANAN PRODUK BERDAFTAR

Date: 15 October 2023 - 5:21am

Garis Panduan ini adalah digunakan sebagai rujukan/panduan tentang perkara-perkara yang harus dipatuhi dalam merangka iklan produk ubat berdaftar untuk kelulusan Lembaga Iklan Ubat. Garis Panduan ini akan mengganti Garis Panduan Pengiklanan Ubat dan Produk Perubatan kepada Orang Ramai. Tarikh penguatkuasaan garis panduan ini adalah pada 1 Oktober 2022.  

Sekiranya tuan/puan mempunyai sebarang pertanyaan lanjut, sila hubungi Sekretariat Lembaga Iklan Ubat di talian 03-78413200 atau melalui emel liu@moh.gov.my.
 

Garis Panduan Peminjaman Ubat-ubatan oleh Hospital/Klinik Perubatan Swasta dari Hospital di bawah KKM Semasa Krisis Bekalan Ubat-ubatan di Pasaran Malaysia

Date: 15 October 2023 - 5:22am

Garis panduan ini bertujuan untuk menguatkuasakan pemakaian Panduan Peminjaman Ubat-ubatan oleh hospital/Klinik Perubatan Swasta dari Hospital di bawah Kementerian Kesihatan Malaysia (KKM) semasa Krisis Bekalan Ubat-ubatan di Pasaran Malaysia.

Panduan ini adalah untuk rujukan mana-mana Pengamal Perubatan Swasta dari sesebuah hospital atau klinik perubatan swasta yang berdaftar di bawah Akta Kemudahan dan Perkhidmatan Jagaan Kesihatan Swasta 1998 [Akta 586] yang ingin membuat peminjaman bekalan ubat-ubatan berkaitan isu krisis bekalan ubat di pasaran Malaysia.

English

COST-BENEFIT ANALYSIS OF THE MEDICINES PRICE MECHANISM

Date: 15 October 2023 - 5:22am

Regulatory Impact Analysis (RIA) is a systematic process of identifying and assessing the likely impact of the proposed regulation using a consistent analytical method, such as cost-benefit analysis (CBA). RIA is a requirement by Malaysia Productivity Corporation (MPC) for any agencies intended to implement changes in the regulation.

English

Guidelines for Authors – Journal of Pharmacy Quality Improvement Initiatives (PharmQIIs)

Date: 2 July 2024 - 7:50am

The Journal of Pharmacy Quality Improvement Initiatives (PharmQIIs) is a peer-reviewed journal published by the Pharmaceutical Services Programme (PSP), Ministry of Health Malaysia (MOH) since 2022. PharmQIIs is set to publish manuscripts derived from Quality Improvement Initiatives (QIIs) that are conducted in Quality Improvement Reports (QIR) format.

ANTIDOTE QUICK GUIDE (ADULT DOSE)

Date: 12 April 2022 - 2:16pm

This guideline is prepared to facilitate the healthcare personnel to react fast. It is hoped to provide guidance to emergency personnel on proper storage, selection, availability, and proper use to reducing poisoning and overdose injuries or deaths by assisting in the early recognition of toxic exposures and guiding emergency personnel on the proper storage, selection, availability, and proper use of antidotal therapies. This guideline will assist in the promotion of quality clinical care pharmacy services throughout Ministry of Health facilities.

English

Medicine Prices Monitoring Survey in Malaysia 2020

Date: 8 March 2022 - 7:58am

Medicine Prices Monitoring Survey in Malaysia / Kajian Pemantauan Harga Ubat (KPHU) is a commitment of the Pharmaceutical Services Program (PSP) to provide comprehensive information on the availability, price and affordability of medicines in Malaysia. The study conducted since 2006 requires cooperation between Malaysia's public and private healthcare sectors. The selection of facilities and medicines was based on the World Health Organization (WHO) and Health Action International (HAI) guidelines.

English

Clients' Charter Achievement 2022

Date: 15 October 2023 - 5:22am

CLIENTS' CHARTER ACHIEVEMENT

January - May 2022

 

Pages